BioVaxys Broadens Intellectual Property Portfolio Commercial Trademark Application Filed for CoviDTH Diagnostic
USA - English
News provided by
Share this article
Share this article
VANCOUVER, B.C., April 29, 2021 /PRNewswire/ BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: BVAXF) ( BioVaxys or the Company ), the world leader in haptenized antigen vaccines for antiviral and cancer applications, announced today that it has filed with the United States Patent & Trademark Office ( USPTO ) an intent-to-use application to register the mark CoviDTH®, it s novel disposable T-cell immune response diagnostic for SARS-CoV-2.
BioVaxys President and CEO Kenneth Kovan commented As we get closer to market, we needed to register a trademark that would be descriptive, memorable, and defendable. CoviDTH® is an ideal mark as it combines the letters DTH, or delayed type hypersensitivity, the mechanism behind our T-cell immune response diagnostic, with Covid-19.
BioVaxys Broadens Intellectual Property Portfolio Commercial Trademark Application Filed for CoviDTH® Diagnostic
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Biovaxys And The World Ovarian Cancer Coalition Join Forces For May 8th, World Ovarian Cancer Day
troyrecord.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from troyrecord.com Daily Mail and Mail on Sunday newspapers.